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China is facing the great challenge of serving the world’s largest rare disease population. It is necessary to develop a
specific medical plan to increase the levels of optimal prevention, diagnosis and treatment of rare diseases under the
existing clinical service structures in China. In 2013, China launched its first pilot project focused on 20 representative
rare diseases. A national network including approximately 100 provincial or municipal medical centers has been
established to enable collaboration on rare diseases across China. The main objectives for this project are to develop
and apply medical guidelines and clinical pathways for rare diseases, to establish a rare disease patient registry and
data repository system, and to promote molecular testing for rare genetic disorders. This project also emphasizes
building close links among the collaborative network, clinicians on the frontlines in basic medical services institutions
and rare disease patient organizations. Primarily, this project expects to develop an actionable medical services plan to
increase the delivery of quality healthcare for individuals and families living with rare diseases in China within five years.Background
China’s is facing the great challenge of servicing the
world’s largest rare disease population. Although several
medical strategies critical to discovery and treatment of
rare diseases have been implemented in China, such as
newborn screening [1], and medical expenses reimburse-
ment for children with congenital heart disease and
leukemia [2], the Chinese public health insurance system
does not cover the specific medical requirement of most
rare diseases patients nor internationally recognized
orphan drugs due to a lack of legislation.
For the most part, Western countries, which have orphan
drug or rare disease legislation with mandates for research
and services, also have some plan of action and/or manage-
ment of rare diseases. While this does not lead to uniform
healthcare services throughout these countries, there
are not the great disparities in terms of geographic regions
and hospital levels, as there is in China [3]. This makes it
difficult for China to closely model many aspects of the
rare disease healthcare systems implemented in Western
countries. Therefore, exploration of the status quo, poten-
tial implementation of known models, and the creation
of new models, is urgently needed to increase optimal* Correspondence: samshjx@sina.com
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stated.prevention, timely diagnosis, and quality treatment of
rare diseases in China in the context of the current
healthcare system and beyond.
There are three great challenges in improving healthcare
for rare diseases in China. First, a general lack of informa-
tion about these conditions, and rare diseases in general,
often leads to delayed diagnosis and misdiagnosis or
inappropriate treatments for a significant proportion of
patients with rare disease. Medical guidelines and clinical
pathways are valuable for patients with rare diseases in
optimizing clinical outcomes and maximizing clinical effi-
ciency. The Ministry of Health (MOH) of China began to
launch the pilot implementation of clinical pathways from
December 2009, and nearly half of China’s public-funded
hospitals have implemented the clinical pathways. Up
to February 2013, the MOH have released 331 clinical
pathways for diseases under 24 disciplines (http://www.
ch-cp.org.cn/?action-zhengcejiedu). However, most of these
guidelines are designed for common and high incidence
diseases; only 46 clinical pathways (13.9%) were developed
for rare diseases. Furthermore, these clinical pathways
still have problems in recording, editing, and statistics
[4]. Secondly, a general lack of patient registry and data
repository systems limits the initiation of epidemiologic
studies and multi-center clinical trials on rare diseases.
And the lack of important epidemiological data and regis-
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the causative gene has been discovered for approximately
80% of rare diseases. Currently, genetic tests are usually
unavailable for most of the patients with rare genetic
diseases and their doctors because of the scarcity of
molecular diagnostic resources and their associated high
costs in China. In a Chinese literature review on genetic
skeletal diseases, genetic mutation testing was performed
in only a small portion of patients (187 of 16,099 cases,
1.16%) by several university hospitals, and then only for
research objectives [6].
To address the rare disease care challenges delineated
above, in 2013, China launched its first pilot national-
level project to promote the advancement of rare disease
healthcare levels. To conduct this project, a national
collaborate network involving more than 100 provincial
and municipal medical centers was established by China
Rare Diseases Prevention and Treatment Alliance. This
network covers 13 provinces, which have a population
of 0.7 billion.
The frames of the project
This project selected 20 representative rare diseases as
pilot diseases including arrhythmogenic right ventricular
cardiomyopathy, congenital myotonia, congenital pyriform
sinus fistula, Duchenne and Becker muscular dystrophy,
epidermolysis bullosa, Fahr syndrome, familial aortic
aneurysm, hereditary spastic paraplegia, left ventricular
noncompaction, Marfan syndrome, myotonic dystrophy,
neurofibromatosis, osteogenesis imperfecta, primary teth-
ered spinal cord syndrome, primary cardiac sarcomas,
pseudoxanthoma elasticum, Sturge-Weber syndrome, thor-
acic aortic aneurysm and dissection, tuberous sclerosis
complex, and Wilson Disease. The selection was based
on the following characteristics: 1) typical rare diseases with
low prevalence but not extremely rare; 2) life-threatening
or chronically debilitating but not classified as inadequately
treated diseases; and 3) scarcity of experienced physicians
specialized in the treatment of these rare diseases except
in very few medical centers across the country, and no
corresponding medical guideline and clinical pathway
has been proposed.
The first aim of this project is to develop and pilot-test
medical guidelines and clinical pathways for 20 example
rare diseases. In particular, the project will focus on
enforcing polycentric pilot-tests for medical guidelines
and clinical pathways of rare diseases, developing standard
models and templates to improve associated or emerging
checklists, and prioritizing items for further evaluation.
The project is first committed to organizing experienced
medical centers specializing in the abovementioned 20
rare diseases and to establishing the corresponding
medical guidelines and clinical pathways. In the second
stage, these rare diseases medical guidelines and clinicalpathways will be pilot-tested in approximately 100 pro-
vincial or municipal medical centers within the national
collaborative network. During the pilot testing, the criteria
will be modified to maximize the agreement and adoption
between hospitals. Then, the revised medical guidelines
and clinical pathways will be submitted to committees of
experts from the MOH and Chinese Medical Association
for review to be further applied in hospitals nationwide.
The second objective of this project is to establish a
patient registry and data repository for 20 example rare
diseases through the national rare diseases network, in-
cluding more than 100 provincial and municipal medical
centers. The inpatient medical records of these medical
centers from 2003 to 2012 will be first retrospectively
reviewed to identify cases of the 20 example rare diseases
from the past 10 years. Then, newly diagnosed example
rare diseases cases will be prospectively registered from
2013–2016. A data repository of de-identified patient
data will be aggregated in a standardized manner, using
Common Data Elements (CDEs) and standardized termin-
ology. In addition, we have developed a web-based open-
source patient registry system that will be released to the
public, as a service to the patient organizations and others,
to allow and encourage them to establish additional rare
disease patient registries.
Third, this project aims to establish a supporting molecu-
lar genetic testing center for rare diseases. Next-generation
sequencing (NGS) technologies could offer fast, compre-
hensive and cost-efficient genetic screening for genetic
diseases and have been successfully adopted in the genetic
diagnostics of some rare diseases with genetic heterogeneity,
such as cardiomyopathies [7,8]. In an attempt to increase
the utility of gene tests in the diagnosis and treatment of
Chinese rare genetic disorders, in this project, the pilot
supporting molecular genetic testing center is critical
component in advancing better care for individuals and
families. Initially, nine single gene and seven NGS-based
panel analyses covering 15 example rare diseases will be de-
veloped to support molecular genetic diagnostic services.
Challenges in implementing the project
Because of their scarcity, it is often difficult for frontline
doctors to identify individual rare diseases conditions in
China, especially the doctors in primary hospitals (< 100
bed) and secondary hospitals (>100 but <500 bed), which
are mainly responsible for treating rural residents and
account for more than 70% of the medical resources in
China. This is not unlike a challenge in the United States
where more than 86% of patients are seen in community
centers and not in specialty centers. In Europe, there is a
delay in diagnosis for 50% of patients, even though centers
of excellence exist for the diseases surveyed [9]. Therefore,
bridging the gap between frontline clinicians and our
collaborated network represents a large challenge in
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project will launch a national continuing education cam-
paign to increase knowledge and awareness of rare diseases
for frontline doctor in low-level medical resources. The
campaign will primarily focus on the abovementioned
20 example rare diseases.
Patient organizations and their members play an active
and instrumental role in improving the healthcare levels
of rare diseases. Recently, several patient organizations
have been established, but they are still limited. The pro-
ject is also committed to exploring strategies to support
more patient organizations in China through our national
collaborative rare diseases network, with a particular focus
on example rare diseases.
Expected outcomes and future prospects
Within the frame of the project, a coordinated and struc-
tural network for rare diseases at the country level could
be established. Improvements in example rare disease
healthcare levels will be assessed. The strengthening of
genetic testing services together with the establishment of
medical guidelines and clinical pathways should enable
the diagnosis of the pilot diseases of interest and appropri-
ate treatment within a reasonable period of time. Analysis
of data from the rare disease patient registry and reposi-
tory system would be helpful for evaluating the prevalence,
regional distribution and expense of rare diseases, which
will provide an important reference for health authorities
when drafting medical policies on rare diseases and
orphan drugs. This project is also committed to increasing
the recognition of rare diseases in the public and doctors
at low-level hospitals. We hope a prevention and treat-
ment pattern suitable for China can be developed by this
explorative project. In the long term, we will look for
methods to scale up and apply the medical system to
200 to 300 rare diseases over the next five years. Chinese
experience and strategies will also provide references to
other countries when they confront their own rare disease
healthcare challenges.
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